Literature DB >> 21115748

Ohtahara syndrome with biotinidase deficiency.

Pratibha Singhi1, Munni Ray.   

Abstract

Ohtahara syndrome is a rare epileptic encephalopathy in infants; the underlying etiology is generally thought to be structural brain malformations. The authors present a rare case of this type of epileptic encephalopathy in which a treatable metabolic condition such as biotinidase deficiency was suspected and diagnosed, and early institution of appropriate therapy led to a good clinical outcome.

Entities:  

Mesh:

Year:  2010        PMID: 21115748     DOI: 10.1177/0883073810383018

Source DB:  PubMed          Journal:  J Child Neurol        ISSN: 0883-0738            Impact factor:   1.987


  5 in total

1.  Status of Newborn Screening and Inborn Errors of Metabolism in India.

Authors:  Seema Kapoor; B K Thelma
Journal:  Indian J Pediatr       Date:  2018-05-07       Impact factor: 1.967

2.  Epilepsy in biotinidase deficiency after biotin treatment.

Authors:  Salvador Ibáñez Micó; Rosario Domingo Jiménez; Eduardo Martínez Salcedo; Helena Alarcón Martínez; Alberto Puche Mira; Carlos Casas Fernández
Journal:  JIMD Rep       Date:  2011-11-04

Review 3.  Current Treatment Options for Early-Onset Pediatric Epileptic Encephalopathies.

Authors:  Rolla Shbarou
Journal:  Curr Treat Options Neurol       Date:  2016-10       Impact factor: 3.598

4.  CDKL5 and ARX mutations in males with early-onset epilepsy.

Authors:  Ghayda M Mirzaa; Alex R Paciorkowski; Eric D Marsh; Elizabeth M Berry-Kravis; Livija Medne; Asem Alkhateeb; Art Grix; Elaine C Wirrell; Berkley R Powell; Katherine C Nickels; Barbara Burton; Andrea Paras; Katherine Kim; Wendy Chung; William B Dobyns; Soma Das
Journal:  Pediatr Neurol       Date:  2013-05       Impact factor: 3.372

Review 5.  Treatment, Therapy and Management of Metabolic Epilepsy: A Systematic Review.

Authors:  Vanessa Lin Lin Lee; Brandon Kar Meng Choo; Yin-Sir Chung; Uday P Kundap; Yatinesh Kumari; Mohd Farooq Shaikh
Journal:  Int J Mol Sci       Date:  2018-03-15       Impact factor: 5.923

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.